Clinical trials often seek to determine the equivalence, non-inferiority, or superiority of an experimental condition (e.g., a new drug) compared to a control condition (e.g., a placebo or an already existing drug). The use of frequentist statistical methods to analyze data for these types of designs is ubiquitous. Importantly, however, frequentist inference has several limitations. Bayesian inference remedies these shortcomings and allows for intuitive interpretations. In this article, we outline the frequentist conceptualization of equivalence, non-inferiority, and superiority designs and discuss its disadvantages. Subsequently, we explain how Bayes factors can be used to compare the relative plausibility of competing hypotheses. We present baymedr, an R package that provides user-friendly tools for the computation of Bayes factors for equivalence, non-inferiority, and superiority designs. Detailed instructions on how to use baymedr are provided and an example illustrates how already existing results can be reanalyzed with baymedr.
Introduction
Researchers generally agree that the clinical trial is the best method to compare the effects of medications and treatments (e.g., E. Christensen, 2007; Friedman, Furberg, DeMets, Reboussin, & Granger, 2010) . Although clinical trials are similar in design, different statistical procedures need to be employed depending on the nature of the research question. Commonly, clinical trials seek to determine the superiority, equivalence, or non-inferiority of an experimental condition (e.g., a new medication) compared to a control condition (e.g., a placebo or an already existing medication; Lesaffre, 2008; Piaggio, Elbourne, Pocock, Evans, & Altman, 2012) . For these kinds of goals, statistical inference is often conducted in the form of testing.
Usually, the frequentist approach to statistical testing forms the framework in which data for these research designs are analyzed (Chavalarias, Wallach, Li, & Ioannidis, 2016) .
In particular, a null hypothesis significance test (NHST) is conducted and evidence is quantified by a p-value. The resulting p-value represents the probability of obtaining a test statistic at least as extreme as the one observed, assuming that the null hypothesis is true.
In other words, the p-value is an indicator of the unusualness of the obtained test statistic under the null hypothesis, forming a 'proof by contradiction' (R. Christensen, 2005) . If the p-value is smaller than a predefined Type I error rate (α), typically set to α = 0.05 (but see, e.g., Benjamin et al., 2018) , we reject the null hypothesis; otherwise we fail to reject the null hypothesis. Importantly, however, the NHST approach to inference has been increasingly critiqued due to certain limitations and erroneous interpretations of p-values (e.g., Berger & Sellke, 1987; Cohen, 1994; Dienes, 2011; Gigerenzer, Krauss, & Vitouch, 2004; Goodman, 1999a Goodman, , 1999b Goodman, , 2008 Loftus, 1996; van Ravenzwaaij & Ioannidis, 2017; Wagenmakers, 2007; Wagenmakers et al., 2018; Wasserstein & Lazar, 2016; Wetzels et al., 2011) . As a result, some methodologists have argued that p-values should be mostly abandoned from scientific practice (see, e.g., Berger & Delampady, 1987; Goodman, 2008; Wagenmakers et al., 2018) .
An alternative to NHST is statistical testing using a Bayesian approach. Bayesian statistics is based on the idea that the credibility of well-defined possibilities, parameters, or models (e.g., null and alternative hypotheses) are updated based on new observations (Kruschke, 2015) . With exploding computational power and the rise of Markov chain Monte Carlo methods (e.g., Gilks, Richardson, & Spiegelhalter, 1995; van Ravenzwaaij, Cassey, & Brown, 2018) that are utilized to estimate probability distributions that cannot be determined analytically, applications of Bayesian inference have recently become tractable. Indeed, Bayesian methods are seeing more and more use in the biomedical field (Berry, 2006) and other disciplines (e.g., psychology; van de Schoot, Winter, Ryan, Zondervan-Zwijnenburg, & Depaoli, 2017) .
Despite of this slowly developing paradigm shift away from frequentist towards Bayesian inference, a majority of biomedical research still employs frequentist statistical techniques (Chavalarias et al., 2016) . To some extent, this might be due to a biased statistical education in favor of frequentist inference. Moreover, researchers might perceive conducting of statistical inference through NHST and reporting of p-values as prescriptive and, hence, adhere to this convention (see, e.g., Gigerenzer, 2004; Winkler, 2001) . We believe that one of the most crucial factors is the unavailability of easy-to-use Bayesian tools and software, leaving Bayesian data analysis largely to statistical experts. Fortunately, important advances have been made towards user-friendly interfaces for Bayesian analyses with the release of the BayesFactor software (Morey & Rouder, 2018) , written in R (R Core Team, 2019), and point-and-click software like JASP (JASP Team, 2019) and Jamovi (The jamovi project, 2019), both of which are based to some extent on the BayesFactor software (Morey & Rouder, 2018) . However, these tools were mainly developed for research designs in the social sciences. Easy-to-use Bayesian tools and corresponding accessible software for the analysis of common biomedical research designs (e.g., superiority, equivalence, and noninferiority) are still missing and, thus, urgently needed.
In this article, we describe how to perform Bayesian inference for superiority, equivalence, and non-inferiority designs. Firstly, we outline the more traditional frequentist approach to statistical testing for each of these designs. Secondly, we discuss the key disadvantages and potential pitfalls of this approach and motivate why Bayesian inferential techniques are better suited for these research designs. Thirdly, we explain the conceptual background of Bayes factors. Fourth, we provide and introduce baymedr (Linde & van Ravenzwaaij, 2019 ; the development version of baymedr is available on GitHub: https://github.com/maxlinde/baymedr), an open-source software written in R (R Core Team, 2019) for the computation of Bayes factors (e.g., Jeffreys, 1939 Jeffreys, , 1948 Jeffreys, , 1961 Kass & Raftery, 1995) for common biomedical designs. We provide step-by-step instructions on how to use baymedr. Finally, we present a reanalysis of an existing empirical study to illustrate the most important features of baymedr.
2 Frequentist Inference for Superiority, Equivalence, and
Non-Inferiority Designs
The superiority, equivalence, and non-inferiority tests are concerned with research settings in which two conditions (e.g., control and experimental) are compared on some outcome measure (E. Christensen, 2007; Lesaffre, 2008) . For instance, researchers might want to investigate whether a new antidepressant medication is superior, equivalent, or non-inferior compared to a well-established antidepressant. The three research designs are quite similar in that they all contain some form of between-group comparison of a summary statistic (typically the mean). Typically, this between-group comparison is made with the t-test.
The three designs differ, however, in the precise specification of the t-test (see Fig 1) . In the following, we will assume that higher scores on the measure of interest represent a more favorable outcome (i.e., superiority or non-inferiority) than lower scores. For example, high scores are favorable when the measure of interest represents the number of social interactions, whereas low scores are favorable when the outcome variable is the number of depressive symptoms. Moreover, throughout this article, the true population effect size (δ) reflects the true standardized difference in the outcome between the experimental condition and the control condition (i.e., δ = (µ exp − µ con ) /σ pooled ).
The Superiority Design
The superiority design tests whether the experimental condition is superior to or better than the control condition (see Fig 1) . Conceptually, the superiority design consists of a one-sided test due to its inherent directionality. However, researchers often conduct a twosided test instead and confirm afterwards that the results follow the expected direction. Grey regions mark the null hypotheses and white regions the alternative hypotheses. Note that the diagram assumes that high values on the measure of interest represent superior or non-inferior values.
Given a one-sided test, the null hypothesis states that the true population effect size is zero, whereas the alternative hypotheses states that the true population effect size is larger than zero:
with a two-sided test, the null hypothesis is the same as in the one-sided test and the alternative hypothesis states that the true population effect size is unequal to zero:
where δ represents the true population effect size between the experimental and the control conditions. To test these hypotheses, either a one-or two-tailed t-test is conducted. If the resulting p-value is smaller than α (and the effect size goes in the expected direction in case of the two-tailed test), we reject the null hypothesis and conclude that the experimental condition is superior to the control condition.
The Equivalence Design
The equivalence design tests whether the experimental and control conditions are practically equivalent (see Fig 1) . There are multiple approaches to equivalence testing (e.g., the power approach; see Meyners, 2012 , for an accessible overview). A comprehensive treatment of all approaches is beyond the scope of this article. Here, we focus on a popular alternative: the two one-sided tests procedure (TOST; Lakens, 2017; Lakens, Scheel, & Isager, 2018; Schuirmann, 1987; Senn, 2007; Westlake, 1976 ). An equivalence interval must be defined, which can be based, for example, on the smallest effect size of interest (SESOI; e.g., Lakens, 2017; Lakens et al., 2018) . The specification of the equivalence interval is not a statistical question; thus, it should be set by experts in the respective fields (Meyners, 2012; Schuirmann, 1987) or comply with regulatory guidelines (Garrett, 2003) .
Importantly, however, the equivalence interval should be determined prior to data analysis.
TOST involves conducting two one-sided t-tests, each one with its own null and alternative hypotheses. For the first test, the null hypothesis states that the true population effect size is smaller than the lower boundary of the equivalence interval, whereas the alternative hypothesis states that the true population effect size is larger than the lower boundary of the equivalence interval. For the second test, the null hypothesis states that the true population effect size is larger than the upper boundary of the equivalence interval, whereas the alternative hypothesis states that the true population effect size is smaller than the upper boundary of the equivalence interval. These hypotheses can be summarized as follows:
where ∆ L and ∆ U represent the lower and upper boundaries of the equivalence interval, respectively. Two p-values (p 1 and p 2 ) result from the application of the TOST procedure. We reject the null hypothesis of non-equivalence and, thus, establish equivalence if max (p 1 , p 2 ) < α (Meyners, 2012; Walker & Nowacki, 2011) . In other words, both tests need to reach statistical significance.
The Non-Inferiority Design
In some situations, we are interested in testing whether the experimental condition is noninferior or not worse than the control condition by a certain amount. This is the goal of the non-inferiority design, which consists of a one-tailed test (see Fig 1) . Realistic applications might include a new medication that has fewer undesirable adverse effects (e.g., Chadwick, 1999) , is cheaper (see, e.g., Kaul & Diamond, 2006 , for a discussion), or is easier to administer than the current medication (e.g., Van de Werf et al., 1999) . In these cases, we need to ponder the cost of a somewhat lower or equal effectiveness of the new treatment with the value of the just mentioned benefits (Hills, 2017) . The null hypothesis states that the true population effect size is equal to a predetermined threshold, whereas the alternative hypothesis states that the true population effect size is higher than this threshold:
where nim represents the non-inferiority margin. As the equivalence interval, the noninferiority margin should be defined a priori. The null hypothesis is rejected and noninferiority established if the resulting p-value is smaller than α.
Limitations of Frequentist Inference
Tests of superiority, equivalence, and non-inferiority have great value in biomedical research.
It is the way researchers conduct their statistical analyses that, we argue, should be critically reconsidered. There are several disadvantages associated with the application of NHST to superiority, equivalence, and non-inferiority designs. Here, we limit our discussion to two disadvantages; for a more comprehensive exposition we refer the reader to Goodman (1999a), Rennie (1978) , International Committee of Medical Journal Editors (1997), and Wagenmakers et al. (2018) .
First, researchers need to stick to a predetermined sampling plan (e.g., Rouder, 2014; Schönbrodt & Wagenmakers, 2018; Schönbrodt, Wagenmakers, Zehetleitner, & Perugini, 2017) . That is, it is not legitimate to decide based on interim results to stop data collection (e.g., because the p-value is already smaller than α) or to continue data collection beyond the predetermined sample size (e.g., because the p-value almost reaches statistical significance). In principle, researchers can correct for the fact that they inspected the data by reducing the required significance threshold through one of several techniques (Ranganathan, Pramesh, & Buyse, 2016). However, such correction methods are rarely applied.
Second, with the frequentist framework, it is impossible to quantify evidence in favor of the null hypothesis (e.g., Gallistel, 2009; Rouder, Speckman, Sun, Morey, & Iverson, 2009;  van Ravenzwaaij, Monden, Tendeiro, & Ioannidis, 2019; Wagenmakers, 2007; Wagenmakers et al., 2018) . Oftentimes, the p-value is erroneously interpreted as a posterior probability, in the sense that it represents the probability for the truth of the null hypothesis (e.g., Berger & Sellke, 1987; Gelman, 2013; Goodman, 2008; Haller & Krauss, 2002) . However, a non-significant p-value does not only occur when the null hypothesis is in fact true but also when the alternative hypothesis is true, yet we did not have enough power to detect an effect (Bakan, 1966; van Ravenzwaaij et al., 2019) . As Altman and Bland (1995) put it: "Absence of evidence is not evidence of absence". Still, a large proportion of biomedical studies falsely claim equivalence based on statistically non-significant t-tests (Greene, Concato, & Feinstein, 2000) . Yet, estimating evidence in favor of the null hypothesis is essential for certain designs like the equivalence test (e.g., Blackwelder, 1982; van Ravenzwaaij et al., 2019 ; see also Hoekstra, Monden, van Ravenzwaaij, & Wagenmakers, 2018) .
The TOST procedure (Lakens, 2017; Lakens et al., 2018; Schuirmann, 1987; Westlake, 1976) for equivalence testing provides a workaround for the problem that evidence for the null hypothesis cannot be quantified with frequentist techniques by defining an equivalence interval around δ = 0 and conducting two NHSTs. Without this interval the TOST procedure would inevitably fail (see Meyners, 2012 , for an explanation of why this is the case).
As we will see, the Bayesian equivalence test does not have this restriction; it allows for the specification of an interval as well as a point null hypothesis.
3 Bayesian Tests for Superiority, Equivalence, and Non-
Inferiority Designs
The Bayesian statistical framework provides a logically sound method to update our beliefs about parameters based on new data (e.g., Goodman, 1999b; Kruschke, 2015) . Bayesian inference can be divided into parameter estimation (e.g., estimating a population correlation) and model comparison (e.g., comparing the relative credibilities of the null and alternative hypotheses) procedures (e.g., Kruschke & Liddell, 2018b) . Here, we will focus on the latter approach, which is usually accomplished with Bayes factors (e.g., Jeffreys, 1939 Jeffreys, , 1948 Jeffreys, , 1961 Kass & Raftery, 1995) . In our exposition of Bayes factors in general and specifically for superiority, equivalence, and non-inferiority designs, we mostly refrain from complex equations and derivations. Formulas are only provided when we think that they help to communicate the ideas and concepts. We refer readers interested in the mathematics of Bayes factors to other sources (e.g., Jeffreys, 1961; Kass & Raftery, 1995 Gronau, Ly, & Wagenmakers, 2019) .
The Bayes Factor
Let us suppose that we have two models or hypotheses (H 0 and H 1 ) that we want to contrast. We have prior beliefs about the credibilities of H 0 and H 1 , which are given by the prior probabilities pr (H 0 ) and pr (H 1 ) = 1 − pr (H 0 ). Now, we collect some data D. After having seen the data, we have posterior beliefs about the probabilities that H 0 and H 1 are true, which are given by the posterior probabilities pr (H 0 |D) and pr (H 1 |D). In other words, we update our prior beliefs about the credibilities of H 0 and H 1 by incorporating
what the data dictates we should believe and arrive at our posterior beliefs. This relation is expressed in Bayes' rule. For the calculation of the posterior probability of H 0 , we have:
where pr (H 0 ) represents the prior probability of H 0 , pr (D|H 0 ) denotes the likelihood of
cf. Kruschke, 2015) , and pr (H 0 |D) is the posterior probability of H 0 . Similarly, we can use
Bayes' rule to update our prior belief about H 1 by incorporating the data to arrive at our posterior belief about H 1 :
.
(2)
The marginal likelihood serves as a normalization constant, ensuring that the sum of the posterior probabilities is 1. Without it, however, the posterior is still proportional to the product of the likelihood and the prior. Therefore, for H 0 we can also write:
and similarly for H 1 , we can write:
where ∝ means 'is proportional to'.
Rather than using posterior probabilities for each hypothesis, we can form an odds ratio of the posterior probabilities for H 0 and H 1 . Dividing the posterior probability of H 0 by the posterior probability of H 1 yields:
The quantity pr (H 0 |D) /pr (H 1 |D) represents the posterior odds and the term pr (H 0 ) /pr (H 1 )
is called the prior odds. To get the posterior odds, we have to multiply the prior odds with pr (D|H 0 ) /pr (D|H 1 ), a quantity known as the Bayes factor (Jeffreys, 1939 (Jeffreys, , 1948 (Jeffreys, , 1961 Kass & Raftery, 1995) . The Bayes factor is the amount by which we would update our prior odds to obtain the posterior odds, after taking into consideration the data. For example, if we had prior odds of 2 and the Bayes factor is 24, then the posterior odds would be 48. In the special case where the prior odds is 1, the Bayes factor is equal to the posterior odds.
A major advantage of the Bayes factor is its ease of interpretation. For example, if the Bayes factor (BF 01 , denoting the fact that H 0 is in the numerator and H 1 in the denominator) equals 10, the data are ten times more likely to have occurred under H 0 compared to H 1 . With BF 01 = 0.2, we can say that the data are five times more likely under H 1 compared to H 0 because we can simply take the reciprocal of BF 01 : BF 10 = 1/BF 01 .
What constitutes enough evidence is subjective and certainly depends on the context.
Nevertheless, rules of thumb for evidence thresholds have been proposed. For instance, Kass and Raftery (1995) labeled Bayes factors between 1 and 3 as 'not worth more than a bare mention', Bayes factors between 3 and 20 as 'positive', those between 20 and 150 as 'strong', and anything above 150 as 'very strong', with corresponding thresholds for the reciprocals of the Bayes factors. An alternative classification scheme was already proposed before by Jeffreys (1961) with thresholds at 3, 10, 30, and 100 and similar labels (cf. Lee & Wagenmakers, 2013, for updated labels).
Of course, we need to define H 0 and H 1 . There are multiple ways to do this but for the purpose of this manuscript we will express the hypotheses using effect sizes (δ; see, e.g., Rouder et al., 2009) . For instance, we could compare the null hypothesis H 0 : δ = δ 0 to a two-sided alternative hypotheses (H 1 : δ = δ 0 ) or to one of two one-sided alternative hypotheses (H 1 : δ < δ 0 or H 1 : δ > δ 0 ). Alternatively, we could compare an interval hypothesis for the null hypothesis (H 0 : ∆ L < δ < ∆ U ) with a corresponding alternative
In the most general case, the Bayes factor (i.e., BF 01 ) can be calculated through division of the posterior odds by the prior odds (i.e., rearranging Eq. 5):
accordingly, we can also calculate BF 10 :
Calculating Bayes factors this way often involves solving complex integrals (cf. Wagenmakers et al., 2010), which we will not discuss here. Fortunately, there is a computational shortcut for the specific but very common scenario where we have a point null hypothesis H 0 and an alternative hypothesis H 1 that is free to vary. This shortcut, which is called the Savage-Dickey density ratio (Dickey & Lientz, 1970; Kass & Raftery, 1995 ; see also Wagenmakers et al., 2010 , for an intuitive introduction), is explained in the Appendix.
Until this point in our exposition, we were quite vague about the exact form of the prior for the effect size under H 1 . A specification of the alternative hypothesis as, for example, H 1 : δ = 0 is all that is needed in the frequentist approach; however, the Bayesian approach requires a precise definition of this prior within H 1 . In principle, the prior within H 1 can be defined as desired, satisfying the subjective needs of the researcher for a specific research setting. In fact, this is a fundamental part of Bayesian inference because various priors allow us to express a theory or prior beliefs (e.g., Morey, Romeijn, & Rouder, 2016; Vanpaemel, 2010) . Most commonly, however, default or objective priors are employed that aim to increase the objectivity in specifying the prior of the effect size under H 1 or serve as a default when no specific prior information is available (e.g., Jeffreys, 1961; Rouder et al., 2009 ).
Default Priors
In the situation where we have a point null hypothesis and an alternative hypothesis that involves a range of values, Jeffreys (1961) proposed to use a Cauchy prior with a scale parameter of r = 1 for the effect size under H 1 . This Cauchy distribution is equivalent to a Student's t distribution with one degree of freedom and resembles a standard Normal distribution, except that the Cauchy distribution has less mass at the center but instead heavier tails (see Fig 2; see also Rouder et al., 2009) . Mathematically, the Cauchy distribution is equivalent to a Normal distribution with a mean µ δ and a variance σ 2 δ , which follows an inverse Chi-square distribution with one degree of freedom, and in which σ 2 δ is integrated out (Liang, Paulo, Molina, Clyde, & Berger, 2008; Rouder et al., 2009 ). The scale parameter r defines the width of the Cauchy distribution; that is, half of the mass lies between −r and r. Choosing a Cauchy prior with a location parameter of 0 and a scale parameter of 1 has the advantage that the resulting Bayes factor is 1 in case of completely uninformative data. In turn, the Bayes factor approaches infinity (or 0) for decisive data (Jeffreys, 1961) .
Still, by varying the Cauchy scale parameter, we can set a different emphasis on the prior credibility of a range of effect sizes. More recently, a Cauchy prior scale of r = 1/ √ 2 is used as a golden standard in the BayesFactor software (Morey & Rouder, 2018) , the pointand-click software JASP (JASP Team, 2019), and Jamovi (The jamovi project, 2019). We have adopted this value in our baymedr software. Nevertheless, objective priors are often critiqued (e.g., Kruschke & Liddell, 2018a; Tendeiro & Kiers, 2019) ; more informed priors should be utilized if relevant knowledge is available (cf., e.g., Gronau et al., 2019; Rouder et al., 2009 ; see also Consonni, Fouskakis, Liseo, & Ntzoufras, 2018 , for a comprehensive review). Gronau et al., 2019) . Subsequently, we will showcase baymedr by reanalyzing data of an empirical study by Basner et al. (2019) .
Implementation and Usage of baymedr

Install and Load baymedr
To install the latest release of baymedr from The Comprehensive R Archive Network (CRAN; https://CRAN.R-project.org/package=baymedr), use the following command:
install.packages("baymedr")
Alternatively, the development version of baymedr can be found on GitHub (https:// github.com/maxlinde/baymedr). Further example calculations and instructions can also be found on this website. The development version of baymedr can be installed with the aid of the devtools software (Wickham, Hester, & Chang, 2019) :
install.packages("devtools") devtools::install_github("maxlinde/baymedr")
Once baymedr is installed, it needs to be loaded into memory, after which it is ready for usage:
library(baymedr)
Commonalities Across Designs
For all three research designs, the user has essentially three choices for data input: Once an equivalence, a non-inferiority, or a superiority test is conducted, an informative and accessible output message is printed in the console. For all three designs, this output states the type of test that was conducted and whether raw or summary data were used.
Moreover, the corresponding null and alternative hypotheses are restated and the specified Cauchy prior scale is shown. In addition, the lower and upper bounds of the equivalence interval are presented in case an equivalence test was employed; similarly, the non-inferiority margin is printed when the non-inferiority design was chosen. Lastly, the resulting Bayes factor is shown. To avoid any confusion, it is declared in brackets whether the Bayes factor quantifies evidence towards the null (e.g., equivalence) or alternative (e.g., non-inferiority or superiority) hypothesis.
The Bayesian Superiority Test
The superiority test has a point null hypothesis H 0 : δ = 0 and a two-sided alternative hypothesis H 1 : δ = 0. Additionally, we can also define a one-sided alternative hypothesis:
To do justice to the name of the superiority test, we can define H 1 : δ > 0 in the case where higher values on the measure of interest correspond to 'superiority' (see Fig 1) and
H 1 : δ < 0 in the case where lower values represent 'superiority'.
Using baymedr, we can perform the Bayesian superiority test with the super_bf() function. Depending on the research setting, low or high scores on the measure of interest represent 'superiority', which can be specified by the argument direction. Moreover, since there are diverging practices on whether to conduct a one-or two-sided test for the superiority design, the user can choose one of the two options by using the argument alternative. Since we seek to find evidence for the alternative hypothesis (superiority), the Bayes factor quantifies evidence for H 1 relative to H 0 (i.e., BF 10 ).
The Bayesian Non-Inferiority Test
The non-inferiority test is very similar to the superiority test. For the non-inferiority test we have H 0 : δ < −nim and H 1 : δ > −nim in the case where higher values on the measure of interest represent 'non-inferiority'; and we have H 0 : δ > nim and H 1 : δ < nim in the case where lower values represent 'non-inferiority' (see Fig 1) . Here, nim represents the non-inferiority margin. Note that, in contrast to the superiority test, we do not have a point null hypothesis for the non-inferiority test (cf. van .
The Bayes factor can be calculated with the infer_bf() function. The value for the non-inferiority margin can be specified with the ni_margin argument. The argument ni_margin_std can be used to declare whether the non-inferiority margin was given in standardized or unstandardized units. Lastly, depending on whether higher or lower values on the measure of interest represent 'non-inferiority', one of the options 'high' or 'low' should be set for the argument direction. Here again, we wish to determine the evidence in favor of H 1 ; therefore, the evidence is expressed for H 1 relative to H 0 (i.e., BF 10 ).
The Bayesian Equivalence Test
In the equivalence test, we compare the null hypothesis H 0 : δ < ∆ L OR δ > ∆ U with the alternative hypothesis H 1 : δ > ∆ L AND δ < ∆ U . In fact, these interval hypotheses are necessary for the frequentist equivalence test (see e.g., Meyners, 2012 Several options are possible: A symmetric equivalence interval around δ = 0 is selected in case one value is provided (e.g., interval = 0.3) or a vector of length two, containing the same two values for the lower and upper equivalence interval boundaries, is inserted (e.g., interval = c(-0.3, 0.3)). In contrast, an asymmetric equivalence interval can be specified with a vector of length two (e.g., interval = c(-0.5, 0.3)). Importantly, the implementation of a point null hypothesis is achieved by using either interval = 0 or interval = c(0, 0), which also serves as the default specification. Moreover, the argument interval_std can be used to declare whether the equivalence interval was specified in standardized or unstandardized units.
Extracting Bayes Factors
When the functions for the superiority, non-inferiority, and equivalence designs are directly evaluated (i.e., without assigning them to a variable), a summary of the corresponding analysis and the resulting Bayes factor are printed in the console. It is also possible to store the results of these Bayesian tests in a variable, which contains all information of the test. In certain situations it might be desirable to further manipulate the Bayes factor that is stored in this variable (e.g., taking the reciprocal of the Bayes factor). To this end, the corresponding Bayes factor needs to be extracted from the variable. This can be done with the get_bf() function, which takes the variable as input.
Demonstration of baymedr
To illustrate how baymedr can be used, we provide one example of an empirical study that employed non-inferiority tests to investigate differences in the amount of sleep, sleepiness, and alertness among medical trainees following either standard or flexible duty-hour programs (Basner et al., 2019) . The authors list several disadvantages of restricted dutyhour programs, such as: (1) and (5) "Restricting duty hours may increase the necessity of cross-coverage, contributing to work compression for both interns and more senior residents." (Basner et al., 2019, p. 916 ).
As outlined above, the calculation of Bayes factors for equivalence and superiority tests is done quite similarly to the non-inferiority test, so we do not provide specific examples for those tests. For the purpose of this demonstration, we will only consider the outcome variable sleepiness. Participants were monitored over a period of 14 days and were asked to indicate each morning how sleepy they were by completing the Karolinska sleepiness scale (Åkerstedt & Gillberg, 1990 The null hypothesis was that medical trainees in the flexible program are sleepier by more than a non-inferiority margin than trainees in the standard program. Conversely, the alternative hypothesis was that trainees in the flexible program are not sleepier by more than a non-inferiority margin than trainees in the standard program. The non-inferiority margin was defined as 1 point on the 9-point Likert scale. All relevant summary statistics can be obtained or calculated from Table 1 and the Results section of Basner et al. (2019) . Table 1 indicates that the flexible program had a mean of M = 4.8 and the standard program had a mean of M = 4.7. From the Results section we can extract that sample sizes were n = 205 and n = 193 in the flexible and standard programs, respectively. Further, the margin of the 95% CI of the difference between the two conditions was 0.31 − 0.12 = 0.19.
Finally, lower scores on the sleepiness scale constitute favorable (or non-inferior) outcomes, informing the value for our argument direction.
Using this information, we can calculate the Bayes factor as follows:
infer_bf ( 
Discussion
In this article, we contrasted the common frequentist approach and the Bayesian approach to superiority, equivalence, and non-inferiority designs. We argued that the Bayesian approach should be preferred because the application of NHSTs does not allow quantifying evidence in favor of the null hypothesis (Gallistel, 2009; van Ravenzwaaij et al., 2019; Wagenmakers, 2007; Wagenmakers et al., 2018) and does not allow deviating from a predefined sampling plan (e.g., Rouder, 2014; Schönbrodt & Wagenmakers, 2018; Schönbrodt et al., 2017) . As a constructive alternative, we provided a tutorial to our recently developed baymedr software, that allows for the easy computation of Bayes factors for these biomedical designs. The functionality of baymedr was showcased through a reanalysis of a medical study by Basner et al. (2019) .
The Prior Distribution
There is a heated and ongoing debate in the literature about how to properly define priors.
In particular, it is argued that the specification of the prior distribution is an overly subjective matter and that different prior distributions lead to very different resulting Bayes factors (e.g., Kass & Raftery, 1995; Liu & Aitkin, 2008; Rouder et al., 2009; Sinharay & Stern, 2002; Tendeiro & Kiers, 2019; Vanpaemel, 2010) . Further, it is argued that even objective prior distributions (Jeffreys, 1961; Liang et al., 2008; Rouder et al., 2009) , that try to remove this subjectivity as good as possible, do not fully solve this problem (e.g., Kruschke & Liddell, 2018a; Tendeiro & Kiers, 2019) . Taking, for example, the Cauchy prior on effect size, different Cauchy scales can result in different Bayes factors. Indeed, in certain situations (e.g., with small or moderate sample sizes), the Bayes factor can be sensitive to unreasonably large variations in the prior scale (Rouder et al., 2009) . As a point of demonstration, conducting a two-sided Bayesian superiority test in baymedr with a sample size of n = 100 in each group, a mean difference of d = 0.5, and a standard deviation of SD = 1 in both groups, we obtain BF 10 ≈ 51.6 with a Cauchy prior scale of r = 0.5 and BF 10 ≈ 9.9 with a Cauchy prior scale of r = 5.
This issue can be mitigated by sticking to the default values in the absence of specific information from prior studies. In most scenarios, extremely large effect sizes are not probable and, thus, large values for the Cauchy prior scale should not be chosen (cf. Rouder et al., 2009 ). When prior study information is available, it is possible to utilize this knowledge to inform the decision of the Cauchy prior scale (e.g., Dienes, 2011; Lee & Wagenmakers, 2013; Vanpaemel, 2010) . A compromise between the uninformed and informed prior is a sensitivity/robustness analysis (Berger et al., 1994; Du, Edwards, & Zhang, 2019; Kass & Raftery, 1995; Lee & Wagenmakers, 2013) . The idea behind a robustness analysis is to calculate Bayes factors for a range of Cauchy prior scales. Using this approach, the researcher could report the minimum and maximum Bayes factor obtained through the robustness check and openly acknowledge the variability in the results. A robustness check is already implemented in JASP (JASP Team, 2019) and will be considered in the future for our baymedr software.
We emphasize that even if an unreasonable prior scale was selected, a skeptical reader can recalculate the Bayes factor with his or her own preference for the scale. For this, however, the original researcher must fully disclose the choice of the Cauchy prior scale.
Therefore, we stress the importance of transparency in reporting all data-analytic decisions.
Conclusions
Tests of superiority, equivalence, and non-inferiority are important means to compare the effectiveness of medications and treatments in biomedical research. Despite several limitations, researchers overwhelmingly rely on traditional frequentist inference to analyze the corresponding data for these research designs (Chavalarias et al., 2016) . We believe that Bayes factors (Goodman, 1999b; Jeffreys, 1939 Jeffreys, , 1948 Jeffreys, , 1961 Kass & Raftery, 1995) are an attractive alternative to NHSTs and p-values because they allow researchers to quantify evidence in favor of the null hypothesis (e.g., Gallistel, 2009; van Ravenzwaaij et al., 2019; Wagenmakers, 2007; Wagenmakers et al., 2018) and permit sequential testing and optional stopping (e.g., Rouder, 2014; Schönbrodt & Wagenmakers, 2018; Schönbrodt et al., 2017) .
In fact, we believe that the possibility for optional stopping and sequential testing has the potential to largely reduce the waste of scarce resources. This is especially important in the field of biomedicine, where clinical trials might be expensive or even harmful for participants.
The baymedr software enables researchers to conduct Bayesian superiority, equivalence, and non-inferiority tests. baymedr is characterized by a user-friendly implementation, making it convenient for researchers who are not statistical experts. Furthermore, using baymedr, it is possible to calculate Bayes factors based on raw data and summary statistics, allowing for the reanalysis of published studies, for which the full data set is not available. 
